What is ZS Pharma?
Founded in 2008, ZS Pharma operates at the intersection of advanced material science and therapeutic innovation. The company is primarily recognized for its proprietary ion-trap technology, a platform designed to selectively remove specific ions from the gastrointestinal tract, thereby offering novel treatment pathways for patients with limited therapeutic options. Following its public market debut in 2014, the company solidified its industry standing, eventually being acquired by the AstraZeneca Group in December 2015. This acquisition served as a validation of the company's research-driven approach to challenging the status quo in complex disease states, effectively integrating its specialized pipeline into a broader pharmaceutical infrastructure.
How much funding has ZS Pharma raised?
ZS Pharma has raised a total of $221.6M across 8 funding rounds:
Private Equity
$1.2M
Private Equity
$2M
Private Equity
$792K
Private Equity
$5.3M
Private Equity
$4.3M
Series C
$46M
Series D
$55M
Stock Offering
$107M
Private Equity (2009): $1.2M, investors not publicly disclosed
Private Equity (2010): $2M, investors not publicly disclosed
Private Equity (2010): $792K, investors not publicly disclosed
Private Equity (2011): $5.3M, investors not publicly disclosed
Private Equity (2012): $4.3M, investors not publicly disclosed
Series C (2012): $46M with participation from Devon Park Bioventures, RiverVest Venture Partners, and Salem Partners
Series D (2014): $55M led by Sofinnova Ventures, Adage Capital Management, RiverVest Venture Partners LLC, Salem Partners, RA Capital Management LLC, Devon Park BioVentures, Novo A/S, and Alta Partners
Stock Issuance/Offering (2014): $107M, investors not publicly disclosed
Key Investors in ZS Pharma
RiverVest Venture Partners
RiverVest is a prominent venture capital firm focused on building life science companies to meet significant unmet medical needs through science, strategy, and innovation.
Sofinnova Ventures
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability with a hands-on approach to company building.
RA Capital Management LLC
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies.
What's next for ZS Pharma?
The strategic integration into the AstraZeneca Group marks the final phase of ZS Pharma's independent lifecycle, shifting the focus toward the global commercialization and clinical expansion of its ion-trap platform. With the backing provided by its historical funding rounds, the company is well-positioned to leverage the resources of a major multinational pharmaceutical entity to accelerate the delivery of its treatments to the medical community. Future developments will likely center on the scalability of its manufacturing processes and the exploration of new therapeutic indications, ensuring that the initial promise of its proprietary technology is fully realized within the competitive landscape of modern medicine.
See full ZS Pharma company page
